18F-fluoroestradiol PET: current status and potential future clinical applications
GJ Liao, AS Clark, EK Schubert… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Estrogen receptor (ER) expression in breast cancer is associated with a more favorable
prognosis and is necessary for a response to endocrine therapies. Traditionally, ER …
prognosis and is necessary for a response to endocrine therapies. Traditionally, ER …
Targeting the androgen receptor in breast cancer
The androgen receptor (AR) is expressed in the majority of breast cancer and across the
three main breast cancer subtypes. Historically, the oncogenic role of AR has best been …
three main breast cancer subtypes. Historically, the oncogenic role of AR has best been …
Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ …
BF Kurland, LM Peterson, JH Lee, EK Schubert… - Clinical Cancer …, 2017 - AACR
Abstract Purpose: 18F-fluoroestradiol (FES) PET scans measure regional estrogen binding,
and 18F-fluorodeoxyglucose (FDG) PET measures tumor glycolytic activity. We examined …
and 18F-fluorodeoxyglucose (FDG) PET measures tumor glycolytic activity. We examined …
18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810 …
Y Wang, KL Ayres, DA Goldman, MN Dickler… - Clinical Cancer …, 2017 - AACR
Abstract Purpose: Evaluate 18F-fluoroestradiol (FES) PET/CT as a biomarker of estrogen
receptor (ER) occupancy and/or downregulation during phase I dose escalation of the novel …
receptor (ER) occupancy and/or downregulation during phase I dose escalation of the novel …
The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[18F] fluoroestradiol (FES), a PET radiotracer …
JA Katzenellenbogen - Nuclear medicine and biology, 2021 - Elsevier
Abstract Introduction 16α-[18 F] Fluoroestradiol (FES), a PET radiotracer for the estrogen
receptor (ER) in breast cancer, was the first receptor-targeted PET radiotracer for oncology …
receptor (ER) in breast cancer, was the first receptor-targeted PET radiotracer for oncology …
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
KJ Andreano, SE Wardell, JG Baker… - Breast cancer research …, 2020 - Springer
Purpose The combination of targeting the CDK4/6 and estrogen receptor (ER) signaling
pathways with palbociclib and fulvestrant is a proven therapeutic strategy for the treatment of …
pathways with palbociclib and fulvestrant is a proven therapeutic strategy for the treatment of …
The Predictive Value of Early Changes in 18F‐Fluoroestradiol Positron Emission Tomography/Computed Tomography During Fulvestrant 500 mg Therapy in Patients …
M He, C Liu, Q Shi, Y Sun, Y Zhang, X Xu… - The …, 2020 - academic.oup.com
Background The aim of this study was to investigate the predictive value of early changes in
18F‐fluoroestradiol (FES) positron emission tomography (PET)/computed tomography (CT) …
18F‐fluoroestradiol (FES) positron emission tomography (PET)/computed tomography (CT) …
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft
SP Govek, JY Nagasawa, KL Douglas, AG Lai… - Bioorganic & medicinal …, 2015 - Elsevier
Selective estrogen receptor degraders (SERDs) have shown promise for the treatment of
ER+ breast cancer. Disclosed herein is the continued optimization of our indazole series of …
ER+ breast cancer. Disclosed herein is the continued optimization of our indazole series of …
Recent advances in imaging steroid hormone receptors in breast cancer
M Kumar, K Salem, AJ Tevaarwerk… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Estrogen receptor (ER) and progesterone receptor (PR) are important prognostic and
predictive biomarkers in breast cancer. PET using ER-and PR-specific radioligands enables …
predictive biomarkers in breast cancer. PET using ER-and PR-specific radioligands enables …
PET imaging agents (FES, FFNP, and FDHT) for estrogen, androgen, and progesterone receptors to improve management of breast and prostate cancers by …
JA Katzenellenbogen - Cancers, 2020 - mdpi.com
Many breast and prostate cancers are driven by the action of steroid hormones on their
cognate receptors in primary tumors and in metastases, and endocrine therapies that inhibit …
cognate receptors in primary tumors and in metastases, and endocrine therapies that inhibit …